NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Recommendation of “Buy” by Analysts

NeoGenomics, Inc. (NASDAQ:NEO) has earned an average recommendation of “Buy” from the nine analysts that are presently covering the company, Marketbeat.com reports. Nine analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $20.25.

Several research analysts have weighed in on NEO shares. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price objective on shares of NeoGenomics in a research note on Wednesday, November 6th. Benchmark reiterated a “buy” rating and issued a $18.00 price objective on shares of NeoGenomics in a research note on Tuesday, September 24th.

NeoGenomics Stock Down 0.1 %

NEO stock opened at $17.73 on Friday. NeoGenomics has a 52-week low of $12.77 and a 52-week high of $21.22. The company’s 50 day simple moving average is $14.75 and its 200-day simple moving average is $14.91. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.99 and a quick ratio of 1.91. The firm has a market capitalization of $2.28 billion, a P/E ratio of -29.07 and a beta of 1.19.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.04. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%. The business had revenue of $167.80 million for the quarter, compared to analyst estimates of $167.00 million. During the same quarter in the previous year, the business earned ($0.06) earnings per share. The firm’s revenue was up 10.5% compared to the same quarter last year. As a group, equities research analysts anticipate that NeoGenomics will post -0.17 EPS for the current year.

Insiders Place Their Bets

In other NeoGenomics news, General Counsel Alicia C. Olivo sold 5,175 shares of the business’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $15.36, for a total value of $79,488.00. Following the completion of the sale, the general counsel now directly owns 37,129 shares of the company’s stock, valued at $570,301.44. The trade was a 12.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.30% of the company’s stock.

Institutional Trading of NeoGenomics

Large investors have recently modified their holdings of the company. Blue Trust Inc. boosted its holdings in shares of NeoGenomics by 107.2% during the 2nd quarter. Blue Trust Inc. now owns 2,331 shares of the medical research company’s stock worth $32,000 after buying an additional 1,206 shares during the period. Quarry LP bought a new stake in shares of NeoGenomics during the 3rd quarter worth $40,000. Canada Pension Plan Investment Board bought a new stake in shares of NeoGenomics during the 2nd quarter worth $57,000. KBC Group NV boosted its holdings in shares of NeoGenomics by 33.1% during the 3rd quarter. KBC Group NV now owns 4,530 shares of the medical research company’s stock worth $67,000 after buying an additional 1,127 shares during the period. Finally, FMR LLC boosted its holdings in shares of NeoGenomics by 7.6% during the 3rd quarter. FMR LLC now owns 13,255 shares of the medical research company’s stock worth $196,000 after buying an additional 931 shares during the period. 98.50% of the stock is owned by institutional investors.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.